{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:57:32Z","timestamp":1786121852831,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Clinical Collaboration Program for Complex and Refractory Diseases Integrating Chinese and Western Medicine\u2014Prostate Cancer","award":["ZDYN-2024-A-084"],"award-info":[{"award-number":["ZDYN-2024-A-084"]}]},{"name":"the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University","award":["No. BJ202504"],"award-info":[{"award-number":["No. BJ202504"]}]},{"name":"the Furong Scholars Program of Hunan Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prostate-specific antigen (PSA) screening lacks specificity, particularly within the 4\u201310\u00a0ng\/mL diagnostic gray zone, leading to unnecessary prostate biopsies and overtreatment. Here, we developed and validated a streamlined urine DNA methylation assay for non-invasive prostate cancer (PCa) detection and biopsy decision-making. Tissue-based Methylated DNA Immunoprecipitation Sequencing (MeDIP-seq) was integrated with large-scale public methylome cohorts to identify PCa-specific hypermethylated regions. Candidate markers were further refined by targeted bisulfite sequencing (TBS) and translated into quantitative PCR (qPCR) assays using post-prostatic massage urine samples. In a retrospective development cohort of 348 participants, stepwise marker selection and logistic regression modelling generated a compact two-gene methylation assay comprising\n                    <jats:italic>ADD3_2<\/jats:italic>\n                    and\n                    <jats:italic>GSX2_2.<\/jats:italic>\n                    The model was then evaluated in an independent prospective multicenter cohort of 200 participants. The assay achieved robust diagnostic performance, with areas under curve (AUC) of 0.86 in the development cohort and 0.91 in the validation cohort, while maintaining specificity above 90%. Performance was preserved in the PSA gray zone and for clinically significant PCa (csPCa). Decision curve analysis (DCA) indicated that integrating this tool could safely avert approximately 55% of unnecessary biopsies without compromising cancer detection. This simple qPCR-based two-gene urine methylation assay provides a scalable, cost-effective and non-invasive complement to PSA-based PCa screening.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00528-y","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:47:49Z","timestamp":1786085269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a two-gene urine DNA methylation assay for noninvasive prostate cancer detection: a prospective multicenter study"],"prefix":"10.1186","volume":"7","author":[{"given":"Dingwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4583-2428","authenticated-orcid":false,"given":"Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"3","key":"528_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2025;87(3):302\u201313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013.","journal-title":"Eur Urol"},{"key":"528_CR2","doi-asserted-by":"publisher","first-page":"e47161","DOI":"10.2196\/47161","volume":"10","author":"X Ruan","year":"2024","unstructured":"Ruan X, Zhang N, Wang D, Huang J, Huang J, Huang D, et al. The impact of prostate-specific antigen screening on prostate cancer incidence and mortality in China: 13-year prospective population-based cohort study. JMIR Public Health Surveill. 2024;10:e47161. https:\/\/doi.org\/10.2196\/47161.","journal-title":"JMIR Public Health Surveill"},{"issue":"5","key":"528_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bju.13437","volume":"118","author":"RW Foley","year":"2016","unstructured":"Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, et al. European randomised study of screening for prostate cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int. 2016;118(5):706\u201313. https:\/\/doi.org\/10.1111\/bju.13437.","journal-title":"BJU Int"},{"issue":"1","key":"528_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.juro.2016.08.103","volume":"197","author":"R Chen","year":"2017","unstructured":"Chen R, Sjoberg DD, Huang Y, Xie L, Zhou L, He D, et al. Prostate-specific antigen and prostate cancer in chinese men undergoing initial prostate biopsies in comparison with western cohorts: data from the PBCG and CPCC. J Urol. 2017;197(1):90\u20136. https:\/\/doi.org\/10.1016\/j.juro.2016.08.103.","journal-title":"J Urol"},{"key":"528_CR5","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. https:\/\/doi.org\/10.1136\/bmj.k3519.","journal-title":"BMJ"},{"issue":"2","key":"528_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.juro.2016.08.081","volume":"197","author":"F Zhao","year":"2017","unstructured":"Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V, et al. Urinary DNA methylation biomarkers for noninvasive prediction of aggressive disease in patients with prostate cancer on active surveillance. J Urol. 2017;197(2):335\u201341. https:\/\/doi.org\/10.1016\/j.juro.2016.08.081.","journal-title":"J Urol"},{"issue":"1","key":"528_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13148-018-0524-x","volume":"10","author":"I Brikun","year":"2018","unstructured":"Brikun I, Nusskern D, Decatus A, Harvey E, Li L, Freije D. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA. Clin Epigenetics. 2018;10(1):91. https:\/\/doi.org\/10.1186\/s13148-018-0524-x.","journal-title":"Clin Epigenetics"},{"issue":"6","key":"528_CR8","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.3892\/ol.2019.11015","volume":"18","author":"K Nekrasov","year":"2019","unstructured":"Nekrasov K, Vikarchuk M, Rudenko E, Ivanitskiy I, Grygorenko V, Danylets R, et al. 6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage. Oncol Lett. 2019;18(6):6917\u201325. https:\/\/doi.org\/10.3892\/ol.2019.11015.","journal-title":"Oncol Lett"},{"issue":"18","key":"528_CR9","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.3390\/cancers14184355","volume":"14","author":"P Krausewitz","year":"2022","unstructured":"Krausewitz P, Kluemper N, Richter AP, B\u00fcttner T, Kristiansen G, Ritter M, et al. Early dynamics of quantitative SEPT9 and SHOX2 methylation in circulating cell-free plasma DNA during prostate biopsy for prostate cancer diagnosis. Cancers (Basel). 2022;14(18):4355. https:\/\/doi.org\/10.3390\/cancers14184355.","journal-title":"Cancers (Basel)"},{"key":"528_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00134","author":"E O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly E, Tuzova AV, Walsh AL, Russell NM, O\u2019Brien O, Kelly S, et al. EpicaPture: a urine DNA methylation test for early detection of aggressive prostate cancer. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.18.00134.","journal-title":"JCO Precis Oncol"},{"key":"528_CR11","doi-asserted-by":"publisher","first-page":"597961","DOI":"10.3389\/fcell.2020.597961","volume":"8","author":"J Guo","year":"2020","unstructured":"Guo J, Liu D, Zhang X, Johnson H, Feng X, Zhang H, et al. Establishing a urine-based biomarker assay for prostate cancer risk stratification. Front Cell Dev Biol. 2020;8:597961. https:\/\/doi.org\/10.3389\/fcell.2020.597961.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"528_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","volume":"10","author":"JJ Tosoian","year":"2024","unstructured":"Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, et al. Development and validation of an 18-gene urine test for high-grade prostate cancer. JAMA Oncol. 2024;10(6):726\u201334. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0455.","journal-title":"JAMA Oncol"},{"issue":"4","key":"528_CR13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.juro.2014.04.098","volume":"192","author":"KJ Lundstr\u00f6m","year":"2014","unstructured":"Lundstr\u00f6m KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014;192(4):1116\u201322. https:\/\/doi.org\/10.1016\/j.juro.2014.04.098.","journal-title":"J Urol"},{"key":"528_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.urology.2016.12.011","volume":"104","author":"MJ Roberts","year":"2017","unstructured":"Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, et al. Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches. Urology. 2017;104:11\u201321. https:\/\/doi.org\/10.1016\/j.urology.2016.12.011.","journal-title":"Urology"},{"issue":"4","key":"528_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.euo.2023.10.029","volume":"7","author":"M Wang","year":"2024","unstructured":"Wang M, Han S, Wu J, Chorneyko A. Diagnostic accuracy of liquid biomarkers for clinically significant prostate cancer detection: a systematic review and diagnostic meta-analysis of multiple thresholds. Eur Urol Oncol. 2024;7(4):689\u2013700. https:\/\/doi.org\/10.1016\/j.euo.2023.10.029.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"528_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.prnil.2018.02.002","volume":"6","author":"S Sriplakich","year":"2018","unstructured":"Sriplakich S, Lojanapiwat B, Chongruksut W, Phuriyaphan S, Kitirattakarn P, Jun-Ou J, et al. Prospective performance of the Prostate Health Index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4\u201310 ng\/mL and negative digital rectal examination. Prostate Int. 2018;6(4):136\u20139. https:\/\/doi.org\/10.1016\/j.prnil.2018.02.002.","journal-title":"Prostate Int"},{"issue":"12","key":"528_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14737159.2023.2277366","volume":"23","author":"M Ferro","year":"2023","unstructured":"Ferro M, Rocco B, Maggi M, Lucarelli G, Falagario UG, Del Giudice F, et al. Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification. Expert Rev Mol Diagn. 2023;23(12):1061\u201370. https:\/\/doi.org\/10.1080\/14737159.2023.2277366.","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"528_CR18","doi-asserted-by":"publisher","first-page":"15193","DOI":"10.1038\/s41598-022-19460-6","volume":"12","author":"J Freds\u00f8e","year":"2022","unstructured":"Freds\u00f8e J, Rasmussen M, Tin AL, Vickers AJ, Borre M, S\u00f8rensen KD, et al. Predicting grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine. Sci Rep. 2022;12(1):15193. https:\/\/doi.org\/10.1038\/s41598-022-19460-6.","journal-title":"Sci Rep"},{"issue":"2","key":"528_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","volume":"25","author":"E Margolis","year":"2022","unstructured":"Margolis E, Brown G, Partin A, Carter B, McKiernan J, Tutrone R, et al. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 2022;25(2):296\u2013301. https:\/\/doi.org\/10.1038\/s41391-021-00456-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"528_CR20","doi-asserted-by":"publisher","first-page":"101870","DOI":"10.1016\/j.xcrm.2024.101870","volume":"5","author":"S Han","year":"2024","unstructured":"Han S, Wang M, Wang Y, Wu J, Guo Z, Wang H, et al. Development and validation of the utLIFE-PC algorithm for noninvasive detection of prostate cancer in urine: a prospective, observational study. Cell Rep Med. 2024;5(12):101870. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101870.","journal-title":"Cell Rep Med"},{"issue":"10","key":"528_CR21","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.3390\/cancers12102993","volume":"12","author":"D Lam","year":"2020","unstructured":"Lam D, Clark S, Stirzaker C, Pidsley R. Advances in prognostic methylation biomarkers for prostate cancer. Cancers (Basel). 2020;12(10):2993. https:\/\/doi.org\/10.3390\/cancers12102993.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"528_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13148-018-0575-z","volume":"10","author":"F Zhao","year":"2018","unstructured":"The Movember Urine Biomarker Consortium, Zhao F, Olkhov-Mitsel E, Kamdar S, Jeyapala R, Garcia J, et al. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clin Epigenetics. 2018;10(1):147. https:\/\/doi.org\/10.1186\/s13148-018-0575-z.","journal-title":"Clin Epigenetics"},{"issue":"Suppl 2","key":"528_CR23","doi-asserted-by":"publisher","first-page":"e1700","DOI":"10.1016\/S2666-1683(20)33739-3","volume":"19","author":"L Dong","year":"2020","unstructured":"Dong L, Xu W, Woon D, Kuk C, Zhu Y, Erlich A, et al. Differences in contemporary biopsy Gleason score distribution in large cohorts of men diagnosed with prostate cancer from China and Canada. Eur Urol Open Sci. 2020;19(Suppl 2):e1700. https:\/\/doi.org\/10.1016\/S2666-1683(20)33739-3.","journal-title":"Eur Urol Open Sci"},{"key":"528_CR24","doi-asserted-by":"publisher","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044. https:\/\/doi.org\/10.3389\/fpubh.2022.811044.","journal-title":"Front Public Health"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00528-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00528-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:47:51Z","timestamp":1786085271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00528-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00528-y","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of the Third Xiangya Hospital, Central South University, in January 2024 (Approval No. Expedited review 24003). All procedures were performed in accordance with the principles of the 1975 Declaration of Helsinki. The trial is registered with the Chinese Clinical Trial Registry (ChiCTR2400081119;\n                      \n                      ). Informative consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lian Tang, Genming Xu, Wei Tang, Jinru Feng, Xiaowei Zeng, and Jinlei Liu are current employees of Yearth Biotechnology Co., Ltd. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"131"}}